News & Information | START In The News

Welcome to START’s News & Information page.  Here you'll find the latest news releases and articles about START. Take a moment to browse through some of the stories that have been written about START.

December 8th, 2010

Prestigious Aspen Cancer Conference moves headquarters to START

San Antonio-based South Texas Accelerated Research Therapeutics will be a sustaining sponsor
November 18th, 2010

Methylgene presents encouraging clinical data for MGCD265 in solid tumor cancers at the 22nd EORTC-NCI-AACR annual meeting

MethylGene Inc. (TSX:MYG) today disclosed safety and efficacy clinical data for MGCD265 in two poster presentations at the 22nd EORTC-NCI-AACR Symposium held in Berlin, Germany. Data was presented for the Company’s two-arm trial (Trial 103) in which MGCD265 is administered in combination with either docetaxel or erlotinib in solid tumor patients. MGCD265 is a proprietary oral multi-targeted receptor tyrosine kinase inhibitor.
November 16th, 2010

START accepts donation from patient to support center in Madrid

San Antonio Business Journal
START Madrid, Spain’s leading Phase I testing center for new anti-cancer drugs, has received an anonymous donation of $279,306 to support its operations.
October 11th, 2010

Local Leading US Phase I Cancer Center Adds Two Key Staff

South Texas Accelerated Research Therapeutics (START) has announced the addition of two key personnel to their clinical roster of medical and nursing staff. START operates the world’s largest Phase I program for clinical trials, with sites in San Antonio and Madrid, Spain.
September 24th, 2010

Genetic Testing Changing Cancer Treatment

KSAT 12 News
By: Jennifer Dodd
START Center Focuses On New Testing
September 24th, 2010

START cancer center unveils new division

San Antonio Business Journal
By: W. Scott Bailey
The START Center for Cancer Care has created a new division, GenomeConsult, that will link oncologists with patient-specific, DNA-based molecular testing to help advance more precise treatments for individuals suffering with cancerous diseases.
September 24th, 2010

Start Center For Cancer Care To Offer Routine, Comprehensive Genomic Profiling Of Patients’ Tumors

San Antonio HCB Magazine
START is the first center in South Texas to make this comprehensive testing routinely available to patients and other oncologists. Testing gives doctors new data for selecting targeted therapies and is being accessed by oncologists in other parts of the world.
September 24th, 2010

Genetic Testing Changing Cancer Treatment

KSAT 12 News
By: Jennifer Dodd
START Center Focuses On New Testing
September 22nd, 2010

San Antonio cancer center selected for new study on human subjects

San Antonio Examiner.com
By: Adolfo Pesquera
ProNaAi Therapeutics Inc., a Kalamazoo, Mich. company, announced Tuesday its first study of a new drug for patients with advanced solid tumors for which no standard therapy exists.
August 17th, 2010

START officials select Japanese oncologist to serve as visiting scholar

San Antonio Business Journal
South Texas Accelerated Research Therapeutics (START) has established a visiting scholar program designed...
July 12th, 2010

La unidad de investigación oncológica en fases I del Grupo HM alcanza su paciente número cien en año y medio

Europa Press
La Unidad del Centro Integral Oncológico Clara Campal asociada al South Texas Accelerated Research Therapeutics de Estados Unidos (CIOCC-START) de fases I en Oncología, perteneciente al Grupo Hospital de Madrid (HM) y ubicada en el Hospital Universitario Sanchinarro (Madrid), ...
June 28th, 2010

Lung cancer clinical trials in San Antonio

San Antonio Business Journal
Web site. Drug name: BAY 73-4506, also known as regorafenib. Location: South Texas Accelerated Research Therapeutics Investigator: Kyriakos Papadopoulos, M.D. Sponsor: Bayer Corporation...
June 28th, 2010

Profiles in Oncology: Amita Patnaik, M.D.

San Antonio Business Journal
By: Sandra Lowe Sanchez
If Amita Patnaik, M.D., can point to one incident that led her to be a research oncologist, it occurred in the intensive care unit at Princess Margaret Hospital in Toronto. Patnaik was a resident in internal medicine when she came across a young patient with metastatic breast cancer. The woman was dying, on a ventilator as the cancer had overtaken her lungs...
June 7th, 2010

Merck chooses START for global anti-cancer effort

San Antonio Business Journal
1,200 patients in 30 to 40 clinical trials each year. START (South Texas Accelerated Research Therapeutics) in San Antonio operates the worldâs largest Phase...
June 3rd, 2010

START Is Named As One Of Only Five US-Based Sites Included In Merck’s New, Pioneering Collaborative Cancer Trials Network

San Antonio HCB Magazine
Merck recently announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer.
June 1st, 2010

Arrowhead Research Announces Clinical Data Presentations at the 2010 ASCO Annual Meeting on June 6, 2010

Arrowhead Research Corporation
PASADENA, Calif. — June 1, 2010 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that interim data from the phase 1 clinical trial conducted by its majority-owned subsidiary, Calando Pharmaceuticals, will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial involves Calando's therapeutic candidate CALAA-01, a formulation of its proprietary delivery system, RONDEL™, and an siRNA sequence targeting cancer. Dr. Antoni Ribas of UCLA's Jonnson Comprehensive Cancer Center will discuss the data in a poster presentation on Sunday, June 6, 2010 at 5:00 p.m. Eastern time.
May 21st, 2010

Banking On A Breakthrough

San Antonio HCB Magazine
Cancer research group launches nation’s only non-government, open access tumor bank, Innovative new tool will accelerate cancer research and the discovery of new treatments worldwide.
May 3rd, 2010

Curis Completes Enrollment of CUDC-101 Phase I Clinical Trial

dBusiness News
Curis is continuing to audit study data, while completing pharmacokinetic and biomarker analyses, and the Company expects that the study's principal investigator, Anthony W. Tolcher, MD, the Director of Clinical Research at South Texas Accelerated Research Therapeutics (START), ...
March 23rd, 2010

Proof in Humans of RNA Interference Using Targeted Nanoparticles

Science Daily
A California Institute of Technology (Caltech)-led team of researchers and clinicians has published the first proof that a targeted nanoparticle -- used as an experimental therapeutic and injected directly into a patient's bloodstream...
March 22nd, 2010

Arrowhead Research (ARWR) Announces Positive Data Related to Subisidiary Testing of RNA Delivery in Humans

StreetInsider.com
The study was led by Professor Mark E Davis and a team of scientists at Caltech It also included researchers and clinicians from UCLA and South Texas Accelerated Research TherapeuticsSTART the two sites conducting Calando's clinical trial The trial which is investigating the safety and ...
March 21st, 2010

Researchers Unveil Scientific Results from siRNA Phase I Clinical Trial in Cancer Patients

AZ-Nanotechnology – The A to Z of Nanatechnology
Researchers Unveil Scientific Results from siRNA Phase I Clinical Trial in Cancer Patients ...is a promising study of a novel cancer agent, and we are proud of our contribution to the initial clinical development of siRNA for the treatment of cancer," says Anthony Tolcher, director of clinical research at South Texas Accelerated Research Therapeutics (START).
January 26th, 2010

Azaya signs up first patient in newest docetaxel drug study

San Antonio Business Journal
The Phase 1 clinical study is being managed by ResearchPoint and is being conducted at South Texas Accelerated Research Therapeutics (START) in San Antonio and The Mary Crowley...
January 22nd, 2010

START win is big step for San Antonio’s biotech push

San Antonio Business Journal
By: W. Scott Bailey
...the ongoing fight against cancer. Their more recent decision to select the South Texas Accelerated Research Therapeutics (or START) Center for Cancer Care as the site where...
January 8th, 2010

Azaya Therapeutics awaits results of cancer-drug study

San Antonio Business Journal
By: Mike W. Thomas
South Texas Accelerated Research Therapeutics (START) has enrolled its first patient in a...
January 5th, 2010

Merck, AstraZeneca pick START to test anticancer compound

San Antonio Business Journal
South Texas Accelerated Research Therapeutics (START) has enrolled its first patient in a phase 1 clinical trial of a combination anticancer regimen made up of two investigational compounds.
January 5th, 2010

First Patient Enrolled In Phase I Clinical Trial Of Landmark Astrazeneca, Merck & Co. Novel Combination Anticancer Regimen

San Antonio Healthcare & Biosciences Magazine
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced recently that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.